SPECTRUM PHARMACEUTICALS INC (SPPI) Fundamental Analysis & Valuation
NASDAQ:SPPI • US84763A1088
Current stock price
1.03 USD
0 (0%)
At close:
1.04 USD
+0.01 (+0.97%)
After Hours:
This SPPI fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. SPPI Profitability Analysis
1.1 Basic Checks
- In the past year SPPI has reported negative net income.
- SPPI had a negative operating cash flow in the past year.
1.2 Ratios
- SPPI has negative profitability rations, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- SPPI has a Gross Margin of 32.34%. This is in the better half of the industry: SPPI outperforms 75.42% of its industry peers.
- The Profit Margin and Operating Margin are not available for SPPI so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 32.34% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. SPPI Health Analysis
2.1 Basic Checks
- SPPI does not have a ROIC to compare to the WACC, probably because it is not profitable.
- Compared to 1 year ago, SPPI has more shares outstanding
- The debt/assets ratio for SPPI is higher compared to a year ago.
2.2 Solvency
- Based on the Altman-Z score of -14.02, we must say that SPPI is in the distress zone and has some risk of bankruptcy.
- With a Altman-Z score value of -14.02, SPPI is not doing good in the industry: 86.78% of the companies in the same industry are doing better.
- SPPI has a Debt/Equity ratio of 1.08. This is a high value indicating a heavy dependency on external financing.
- SPPI has a worse Debt to Equity ratio (1.08) than 83.05% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.08 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -14.02 |
ROIC/WACCN/A
WACC8.97%
2.3 Liquidity
- A Current Ratio of 2.71 indicates that SPPI has no problem at all paying its short term obligations.
- The Current ratio of SPPI (2.71) is worse than 76.44% of its industry peers.
- SPPI has a Quick Ratio of 2.38. This indicates that SPPI is financially healthy and has no problem in meeting its short term obligations.
- SPPI's Quick ratio of 2.38 is on the low side compared to the rest of the industry. SPPI is outperformed by 77.80% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.71 | ||
| Quick Ratio | 2.38 |
3. SPPI Growth Analysis
3.1 Past
- The Earnings Per Share has grown by an impressive 58.62% over the past year.
EPS 1Y (TTM)58.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%75%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
- SPPI is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 39.88% yearly.
- Based on estimates for the next years, SPPI will show a very strong growth in Revenue. The Revenue will grow by 98.74% on average per year.
EPS Next Y88.67%
EPS Next 2Y51.91%
EPS Next 3Y39.88%
EPS Next 5YN/A
Revenue Next Year722.64%
Revenue Next 2Y275.85%
Revenue Next 3Y179.1%
Revenue Next 5Y98.74%
3.3 Evolution
4. SPPI Valuation Analysis
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for SPPI. In the last year negative earnings were reported.
- A Price/Forward Earnings ratio of 7.97 indicates a rather cheap valuation of SPPI.
- Based on the Price/Forward Earnings ratio, SPPI is valued cheaper than 98.98% of the companies in the same industry.
- Compared to an average S&P500 Price/Forward Earnings ratio of 38.88, SPPI is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 7.97 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- SPPI's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- A more expensive valuation may be justified as SPPI's earnings are expected to grow with 39.88% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y51.91%
EPS Next 3Y39.88%
5. SPPI Dividend Analysis
5.1 Amount
- No dividends for SPPI!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
SPPI Fundamentals: All Metrics, Ratios and Statistics
1.03
0 (0%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-10 2023-08-10/bmo
Earnings (Next)11-08 2023-11-08/bmo
Inst Owners0.06%
Inst Owner Change0%
Ins Owners1.22%
Ins Owner Change0%
Market Cap211.40M
Revenue(TTM)25.73M
Net Income(TTM)-64.97M
Analysts50
Price Target1.29 (25.24%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)61.99%
Min EPS beat(2)54.61%
Max EPS beat(2)69.36%
EPS beat(4)3
Avg EPS beat(4)34.68%
Min EPS beat(4)-5.49%
Max EPS beat(4)69.36%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)25.37%
Min Revenue beat(2)11.17%
Max Revenue beat(2)39.57%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-34.6%
EPS NQ rev (1m)0%
EPS NQ rev (3m)44.45%
EPS NY rev (1m)78.12%
EPS NY rev (3m)78.12%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)40.01%
Revenue NY rev (1m)47.89%
Revenue NY rev (3m)47.89%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 7.97 | ||
| P/S | 8.22 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 7.89 | ||
| P/tB | 7.89 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.36
EYN/A
EPS(NY)0.13
Fwd EY12.54%
FCF(TTM)-0.43
FCFYN/A
OCF(TTM)-0.43
OCFYN/A
SpS0.13
BVpS0.13
TBVpS0.13
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 32.34% | ||
| FCFM | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.24
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.08 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 155.46% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.71 | ||
| Quick Ratio | 2.38 | ||
| Altman-Z | -14.02 |
F-Score3
WACC8.97%
ROIC/WACCN/A
Cap/Depr(3y)772.71%
Cap/Depr(5y)966.68%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)58.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%75%
EPS Next Y88.67%
EPS Next 2Y51.91%
EPS Next 3Y39.88%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year722.64%
Revenue Next 2Y275.85%
Revenue Next 3Y179.1%
Revenue Next 5Y98.74%
EBIT growth 1Y50.42%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y30.33%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y28.22%
OCF growth 3YN/A
OCF growth 5YN/A
SPECTRUM PHARMACEUTICALS INC / SPPI Fundamental Analysis FAQ
What is the ChartMill fundamental rating of SPECTRUM PHARMACEUTICALS INC (SPPI) stock?
ChartMill assigns a fundamental rating of 2 / 10 to SPPI.
What is the valuation status for SPPI stock?
ChartMill assigns a valuation rating of 4 / 10 to SPECTRUM PHARMACEUTICALS INC (SPPI). This can be considered as Fairly Valued.
Can you provide the profitability details for SPECTRUM PHARMACEUTICALS INC?
SPECTRUM PHARMACEUTICALS INC (SPPI) has a profitability rating of 1 / 10.
How financially healthy is SPECTRUM PHARMACEUTICALS INC?
The financial health rating of SPECTRUM PHARMACEUTICALS INC (SPPI) is 2 / 10.
Is the dividend of SPECTRUM PHARMACEUTICALS INC sustainable?
The dividend rating of SPECTRUM PHARMACEUTICALS INC (SPPI) is 0 / 10 and the dividend payout ratio is 0%.